Example: tourism industry
BORTEZOMIB THALIDOMIDE AND DEXAMETHASONE …
Extravasation risk: Irritant: bortezomib EMETIC RISK Low ADVERSE EFFECTS/REGIEMN SPECIFIC COMPLICATIONS • Teratogenic: The Pregnancy Prevention Programme must be observed for all male and female patients. Prescribing and dispensing of thalidomide must be in line with the pregnancy prevention programme.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
CARFILZOMIB /DEXAMETHASONE (CarDex)
nssg.oxford-haematology.org.ukEXTRAVASATION RISK: Carfilzomib is not known to be a vesicant. There are no data available regarding skin corrosion/irritation or extravasation. Follow institution’s guideline on management of extravasation events in the event of carfilzomib extravasation. MHRA alert: risk of reactivation of hepatitis B virus:
Status epilepticus guideline
www.thewaltoncentre.nhs.ukIV access due to risk of extravasation and phlebitis. Preferred if Avoid if Levetiracetam (Keppra) - Polypharmacy (fewest ... quality randomised controlled trial evidence to guide treatment decisions. • Look for an underlying cause and treat ... This guideline will focus on the management of tonic-clonic status epilepticus.
CE 110 - A Guide to Clinical Differential Diagnosis of ...
res.cloudinary.comA Guide to Clinical Differential Diagnosis of Oral Mucosal Lesions Continuing Education ... The first step in successful therapeutic management of a ... Parulis/sinus track Periodontal abscess Mucocele (mucous extravasation phenomenon) Fibrous hyperplasia Inflammatory papillary hyperplasia Necrotizing sialometaplasia ...
Quick Reference Guide - MRSA Topical Eradication
www.swagcanceralliance.nhs.ukExtravasation Oxaliplatin is an exfoliant (Group 4). ... management and prognosis is not particularly strong. Coronary artery spasm is more common in patients receiving continuous infusions of fluorouracil, and is usually ... Quick Reference Guide - …
GUIDE TO EXTRAVASATION MANAGEMENT IN ADULT & …
emcrit.orgGUIDE TO EXTRAVASATION MANAGEMENT IN ADUL T & PEDIATRIC PATIENTS. Large, well-designed, controlled clinical trials in humans are not available to support the development of extravasation management guidelines. Available data generally consists o. f case reports, trials utilizing animal models, and small studies with evidence of poor or ...